Enhanced PTH Compounds with Improved Pharmacokinetic Profiles

The present inventive concept relates to novel PTH compounds and formulations exhibiting improved pharmacokinetic profiles, characterized by a peak-to-trough ratio of less than 3.5 within one injection interval, enabling more efficient and safer treatment of hypoparathyroidism.

The original patent disclosed PTH compounds with peak-to-trough ratios of less than 4, which, although an improvement, still exhibited limitations in terms of efficacy and administration frequency. The new inventive concept addresses these limitations by introducing conjugated PTH compounds, modified formulations, and optimized delivery systems, thereby providing enhanced therapeutic benefits and patient convenience.

The inventive concept encompasses PTH compounds conjugated to polyethylene glycol molecules, which reduce the peak-to-trough ratio to less than 3.5, allowing for longer administration intervals. Additionally, the concept includes formulations comprising excipients that enhance the stability of the PTH compound, as well as delivery systems utilizing needle-free injection devices or programmed subcutaneous injection devices. These innovations enable more efficient and safer treatment of hypoparathyroidism, reducing the burden on patients and healthcare systems.

The new claims introduce a significant improvement over the original patent by reducing the peak-to-trough ratio to less than 3.5, thereby providing a more stable and efficient therapeutic profile. The conjugation of PTH compounds to polyethylene glycol molecules and the use of optimized delivery systems constitute novel and non-obvious advancements in the field.

Alternative embodiments of the inventive concept may include varying the molecular weight of the polyethylene glycol molecule, using different excipients to enhance stability, or incorporating additional components to further improve the pharmacokinetic profile. Variations of the delivery system may include using different injection devices or programming the device to administer the formulation at varying intervals.

The enhanced PTH compounds and formulations have significant commercial potential in the treatment of hypoparathyroidism, offering improved efficacy, safety, and patient convenience. The target market includes pharmaceutical companies, hospitals, and clinics specializing in endocrinology and hormone therapy.